




Emtricitabine

NOT RECOMMENDED AS AN
ESSENTIAL MEDICINE

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.1. Antiretrovirals](#) >
[Nucleoside/Nucleotide reverse transcriptase inhibitors](#)

EMLc

ATC codes: [J05AF09](#)

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified ICD11 code: 1C62.Z
INN	Emtricitabine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	Emtricitabine (FTC) is an acceptable alternative to lamivudine (3TC), based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.
Formulations	Oral > Liquid: 10 mg per mL Oral > Solid: 200 mg
EML status history	First added in 2007 (TRS 946) Changed in 2007 (TRS 950) Removed in 2015 (TRS 994)
Sex	All
Age	Also recommended for children
Age restriction	>3 months
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents . 
Wikipedia	Emtricitabine 
DrugBank	Emtricitabine 

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the removal of emtricitabine from the EML and EMLc on the basis that listing is not aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1), and also because of the availability of fixed-dose combination formulations containing emtricitabine. References: 1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

